We are live on ! Find out more
ORIA

Orion Biotech Opportunities Corp. Class A Ordinary Share

Delisted

ORIA was delisted on the 28th of April, 2023.

49 hedge funds and large institutions have $145M invested in Orion Biotech Opportunities Corp. Class A Ordinary Share in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less capital invested

Capital invested by funds: $149M → $145M (-$3.88M)

4% less funds holding

Funds holding: 5149 (-2)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

42% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 12

Holders
49
Holders Change
-2
Holders Change %
-3.92%
% of All Funds
0.78%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
7
Reduced
12
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CSS
51
Cubist Systematic Strategies
Connecticut
-$6.32M -629,218 Closed
Millennium Management
52
Millennium Management
New York
-$6.29M -625,504 Closed
FTCM
53
First Trust Capital Management
Illinois
-$2.67M -265,506 Closed
SC
54
Sculptor Capital
New York
-$2.51M -250,000 Closed
TCA
55
Taconic Capital Advisors
New York
-$1.97M -195,000 Closed
DCM
56
DG Capital Management
New York
-$972K -96,319 Closed
ETH
57
Exos TFP Holdings
New York
-$432K -43,029 Closed
UBS Group
58
UBS Group
Switzerland
-$131 -13 Closed

ORIA Hedge Fund Activity: Q1 2023 in Review

49 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) for Q1 2023, worth a combined $145M — down 2.6% from $149M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ORIA and 7 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 7 added.

The largest buyer was Westchester Capital Management (New York), adding an estimated $9.41M. The largest seller was KIM LLC, exiting entirely with an estimated $8.06M sold.

  • 49 institutional investors held Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) as of Q1 2023, down from 51 in Q4 2022.
  • Funds reported $145M of Orion Biotech Opportunities Corp. Class A Ordinary Share stock for Q1 2023, down 2.6% quarter-over-quarter.
  • 7 funds opened new Orion Biotech Opportunities Corp. Class A Ordinary Share positions in Q1 2023 and 9 closed out, a net change of -2 holders.
  • The largest Orion Biotech Opportunities Corp. Class A Ordinary Share buyer in Q1 2023 was Westchester Capital Management (New York), an estimated $9.41M added.
  • The largest Orion Biotech Opportunities Corp. Class A Ordinary Share seller in Q1 2023 was KIM LLC, an estimated $8.06M sold.

Based on aggregated 13F filings for Q1 2023.